Revance(RVNC) - 2024 Q2 - Quarterly Results

Exhibit 99.1 REVANCE Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update – Q2 total DAXXIFY® and RHA® (by Teoxane SA) product revenue of $65.3 million, a YoY increase of 20%. – Q2 DAXXIFY net revenue of $28.7 million, a YoY increase of 27%. – Q2 DAXXIFY aesthetic units sold increased 65% YoY and 15% QoQ; over 3,700 ordering accounts reached. – Q2 RHA Collection net revenue of $36.6 million, a YoY increase of 15%. – Revance launched DAXXIFY for cervical dystonia, with coverage wi ...